WO2024250040 - COVID VACCINE DELIVERED BY HD-MAP
National phase entry is expected:
Publication Number
WO/2024/250040
Publication Date
05.12.2024
International Application No.
PCT/US2024/039247
International Filing Date
24.07.2024
Title **
[English]
COVID VACCINE DELIVERED BY HD-MAP
[French]
VACCIN CONTRE LA COVID ADMINISTRÉ PAR HD-MAP
Applicants **
VAXXAS PTY LIMITED
Suite 304, Level 3, 1 Alfred Street
Sydney, NSW, 2000, AU
HOEY, David
Suite 304, Level 3, 1 Alfred Street
Boston, MA 02115, US
Inventors
BERMINGHAM, Imogen
Vaxxas Pty Limited
Suite 304, Level 3, 1 Alfred Street
Sydney, Nsw, 2000, AU
FORSTER, Angus
Vaxxas Pty Limited
Suite 304, Level 3, 1 Alfred Street
Sydney, Nsw, 2000, AU
BAKER, Ben
Vaxxas Pty Limited
Suite 304, Level 3, 1 Alfred Street
Sydney, Nsw, 2000, AU
MULLER, David
Vaxxas Pty Limited
Suite 304, Level 3, 1 Alfred Street
Sydney, Nsw, 2000, AU
MURUGAPPAN, Senthil
Vaxxas Pty Limited
Suite 304, Level 3, 1 Alfred Street
Sydney, Nsw, 2000, AU
Priority Data
63/470,600
02.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1124 | |
| EPO | Filing, Examination | 6712 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2205 |
Total: 11147 USD
Abstract[English]
A method of immunizing a human against SARS-CoV-2 by administering to the human a HexaPro vaccine composition coated onto a microprojection array (HD-MAP) comprising a base and a plurality of solid microprojections by projecting the microprojection array into the human's skin thereby penetrating the skin with the microprojections coated with the composition such that the vaccine composition is stripped from the microprojections.[French]
L'invention concerne une méthode d'immunisation d'un être humain contre le SARS-CoV-2 par l'administration à l'être humain d'une composition vaccinale HexaPro qui enduit un réseau de microprojections (HD-MAP) comprenant une base et une pluralité de microprojections solides, par projection du réseau de microprojections dans la peau de l'être humain et par pénétration dans la peau des microprojections enduites de la composition en sorte de retirer la composition vaccinale des microprojections.